3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
4
Squamous Cell Carcinoma of Head and Neck
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Sezary Syndrome
1
Myeloid Malignancies
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Interventions
Irinotecan
58
Bevacizumab
56
Oxaliplatin
49
Leucovorin
49
Fluorouracil
49
Capecitabine
45
Cetuximab
44
pembrolizumab
23
IFL protocol
15
Nivolumab
11
regorafenib
10
Panitumumab
10
Celecoxib
8
Radiotherapy
7
Cyclophosphamide
7
atezolizumab
6
Surgical Procedures, Operative
6
Gemcitabine
6
Folfox protocol
6
Colonoscopy
6
trifluridine tipiracil drug combination
5
Neoadjuvant Therapy
5
Metformin
5
Immunohistochemistry
5
Biopsy
5
tislelizumab
4
spartalizumab
4
durvalumab
4
Trastuzumab
4
Mitomycin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colorectal Neoplasms
×
magrolimab
×
Clear all
NCT05330429
2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2
Terminated
77 enrolled
22 charts